Skip to main content Deutsch

Applied and Experimental Oncology

Aims of the research focus

The local invasion into healthy surrounding tissues and the metastatic distribution into the body during progressive disease are still the major reasons for solid tumor lethality. Consequently, the improvement of systemic cancer therapy represents a central medical need with high social relevance.

In a translational research approach comprising a cooperation of multiple scientific disciplines and clinical research partners we focus on the development/identification of 1) innovative treatment strategies with high tumor-specificity and low adverse effects; 2) novel therapy targets either on the tumor cells or in the cancer microenvironment; 3) prognostic and predictive biomarkers and tests for appropriate patient stratification for novel therapeutic interventions; 4) strategies to circumvent or revert therapy resistance based on a detailed elucidation of the underlying molecular mechanisms.

Applied and Experimental Oncology

Coordinator and Group Leader: Univ.-Prof. Mag. Dr. Walter Berger

Further Research Laboratories:
Group Leader: Assoc. Prof. Mag. Dr. Martin Filipits
Group Leader: Assoc. Prof. Priv.-Doz. Mag. Dr. Michael Grusch
Group Leader: Univ.-Prof.in Mag.a Dr.in Petra Heffeter
Group Leader: A.o. Univ.-Prof. Dipl.-Ing. Dr. Klaus Holzmann
Group Leader: Assoc. Prof.in Priv.-Doz.in Mag.a Dr.in Hedwig Sutterlüty

Mainly researched types of cancer:

  • lung cancer
  • colon cancer
  • breast cancer
  • brain tumors (also in children)
  • mesothelioma (asbestos-related cancer)
  • bladder carcinoma
  • melanoma
  • osteosarcoma
  • soft tissue sarcomas (also in animal patients such as dogs)